Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials
…, P Amarenco, TR Pedersen, JC LaRosa… - Journal of the American …, 2014 - jacc.org
Background : Levels of atherogenic lipoproteins achieved with statin therapy are highly
variable, but the consequence of this variability for cardiovascular disease risk is not well-…
variable, but the consequence of this variability for cardiovascular disease risk is not well-…
The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart …
JC LaRosa, D Hunninghake, D Bush, MH Criqui… - Circulation, 1990 - Am Heart Assoc
… Stamler J, Shekelle R: Dietary cholesteroland human coronary heart disease. The …
McGee DL, Reed DM, Yano K, Tillotson J: Ten-year incidence of coronary heart disease in the …
McGee DL, Reed DM, Yano K, Tillotson J: Ten-year incidence of coronary heart disease in the …
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials
…, HM Colhoun, DD Waters, JC LaRosa… - European heart …, 2015 - academic.oup.com
Aims The effect of statins on risk of heart failure (HF) hospitalization and HF death remains
uncertain. We aimed to establish whether statins reduce major HF events. Methods and …
uncertain. We aimed to establish whether statins reduce major HF events. Methods and …
[HTML][HTML] Intensive lipid lowering with atorvastatin in patients with stable coronary disease
JC LaRosa, SM Grundy, DD Waters… - … England Journal of …, 2005 - Mass Medical Soc
Background Previous trials have demonstrated that lowering low-density lipoprotein (LDL)
cholesterol levels below currently recommended levels is beneficial in patients with acute …
cholesterol levels below currently recommended levels is beneficial in patients with acute …
[HTML][HTML] HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
P Barter, AM Gotto, JC LaRosa, J Maroni… - New England journal …, 2007 - Mass Medical Soc
Background High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor
of cardiovascular events. However, it is not clear whether this association is maintained at …
of cardiovascular events. However, it is not clear whether this association is maintained at …
Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials
JC LaRosa, J He, S Vupputuri - Jama, 1999 - jamanetwork.com
ContextLowering low-density lipoprotein cholesterol (LDL-C) is known to reduce risk of recurrent
coronary heart disease in middle-aged men. However, this effect has been uncertain in …
coronary heart disease in middle-aged men. However, this effect has been uncertain in …
Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction
…, J LaRosa, IS Ockene, TA Pearson, J Reed… - Circulation, 1998 - Am Heart Assoc
(CHD), stroke, and other cardiovascular diseases. Framingham research has helped define
the quantitative and additive nature of these causes or, as they are now called,“…
the quantitative and additive nature of these causes or, as they are now called,“…
Association of LDL cholesterol, non–HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta …
…, BJ Arsenault, S Mora, TR Pedersen, JC LaRosa… - Jama, 2012 - jamanetwork.com
Context The associations of low-density lipoprotein cholesterol (LDL-C), non–high-density
lipoprotein cholesterol (non–HDL-C), and apolipoprotein B (apoB) levels with the risk of …
lipoprotein cholesterol (non–HDL-C), and apolipoprotein B (apoB) levels with the risk of …
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets …
…, S Haffner, J Hsia, A Breazna, J LaRosa… - Diabetes …, 2006 - Am Diabetes Assoc
OBJECTIVE—The Treating to New Targets study showed that intensive lipid-lowering therapy
with atorvastatin 80 mg/day provides significant clinical benefit beyond that afforded by …
with atorvastatin 80 mg/day provides significant clinical benefit beyond that afforded by …
[HTML][HTML] Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
…, W Koenig, M Koren, V Krane, MJ Landray, J LaRosa… - The Lancet, 2019 - thelancet.com
Background Statin therapy has been shown to reduce major vascular events and vascular
mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety …
mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety …